

Hybrid Event

October 21-22 2022

Golden Age Hotel Athens - GREECE

θα χορηγηθούν 16 Μόρια Συνεχιζόμενης Ιατρικής Εκπαίδευσης (CME - CPD)

Η εγγραφή είναι δωρεάν

Organized by



Under the auspices of





Secretariat



## 3<sup>rd</sup> International Meeting on Lung Cancer October 21-22 2022

### Welcome Letter

Dear Colleagues,

Dear Friends,

The Covid-19 pandemic has tremendously changed all aspects of public life as well as the scientific activity in the field of Oncology, leading to serious obstacles in the management of patients with cancer. In these difficult conditions, going "against" the adverse environment, we considered that it would be very important and helpful to continue our effort, which aims to achieve a closer contact between the scientific community in Greece and abroad in the field of Thoracic Oncology providing a flexible platform for networking.

This event continues our effort to mobilize Greek physicians and scientists, who live and work abroad or in Greece and who focus on Thoracic Oncology. Our experience from the previous two meetings further supports our notion that this effort could be the basis not only for networking, but also for developing research collaborations as well as for promoting the training of the next generation of cancer researchers. For this purpose, we have decided only a small number of tutorial lectures to be included in the program of this meeting, devoting more time for presentation of research projects of the participants.

We would like to welcome all the participants in the "3rd International Meeting on Lung Cancer" expressing our thanks for your support.

The Organizing & Scientific Committee

P. Christopoulos

Professor of Medicine at Heidelberg University, MD, PhD, Hematologist & Medical Oncologist in the Thoraxklinik and National Center for Tumor Diseases (NCT) at Heidelberg University Hospital, Germany

F. Køinis

MD, PhD, Assistant Professor of Medical Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece F.I. Dimitrakopoulos

MD, PhD, Medicat Oncologist, Division of Oncology & Molecular Oncology Laboratory, Department of Medicine, University of Patras, Greece

D. Papadatos - Pastos

MRCP(UK) PhD, Consultant in Medical Oncology, Lung Cancer and Acute Oncology, University College London Hospitals and The Princess Alexandra Hospital, UK



## 3<sup>rd</sup> International Meeting on Lung Cancer October 21-22 2022

## Friday, 21 October 2022

nα	/.5_NQ	nn	Wal	com	hhe	ress
UO.	4:1-117.	UU	we	COM	e auu	1622

09.00-11.00	SESSION 1: Immunotherapy and Lung Cancer (I)
	Chairs: P. Christopoulos, F. Koinis (GR)

09.00-09.30	Transforming the standard of adjuvant NSCLC treatment	A. Kotsakis (GR)
	,	Sponsored by Roche

early NSCLC	D. Papadatos-Pastos (UK)
10.00-10.30 The landscape of front-line immunotherapy in	
advanced/metastatic NSCLC	D. Ziogas (GR)

09 30-10 00. The emerging relevance of neo-adjuvant immunotherany in

10.30-11.00 Therapeutic options after immunotherapy failure Ch. Charalambous (CY)

#### 11.00-11.30 Coffee Break

#### 11.30-13.00 Lectures

#### Chairs: S. Gennatas (UK), F.I. Dimitrakopoulos (GR)

F. Koinis (GR)	Bi-Specific Agents for immunotherapy in lung cancer	11.30-12.00
	Advances in the antibody drug conjugates therapeutic	12.00-12.30
K. Boleti (UK)	strategies in lung cancer	
	Therapeutic Potential of Tumour Infiltrating Lymphocytes	12.30-13.00
V. Tseveleki (GR)	(TILs) in lung cancer	

# 13.00-14.15 SESSION 2: Immunotherapy and Lung Cancer (I) Current or Future Research Projects Chairs: K. Kosmatopoulos (FR), A. Giatromanolaki (GR)

G. Evangelou (GR)	3.00-13.15 A fish in the service of clinical decision making	
P. Christopoulos (DE)	3.15-13.30 Improved monitoring of ALK+ lung cancer using circulating DNA analysis	
or	3.30-13.45 Combinatorial molecular and immunological biomarkers for	
A. Xagara (GR)	immunotherapy response in NSCLC patients	
G. Tsakonas (SE)	3.45-14.00 Management of CNS metastases in NSCLC	
9	4.00-14.15 Towards efficient cancer immunotherapies: deciphering the	
M. Tsoumakidou (GR)	landscape of antigen-presenting cells	

#### 14.15-15.00 Light Lunch

## 15.00-16.30 SESSION 3: Biomarkers/Immunotherapy in Lung cancer

Chairs: A. Kotsakis (GR), S. Fortis (GR)

Chairs: A. Ko	tsakis (GR), S. Fortis (GR)	
15.00-15.30	Novel mechanisms in immune checkpoint inhibitor resistance	P. Verginis (GR)
15.30-16.00	DNA Damage Response (DDR) gene mutations and HRD status:	
	Are they new emerging biomarkers for	
	the treatment of Thoracic Tumors	Th. Rampias (GR)
16.00-16.30	Patient-derived organoids for precision lung cancer	
	immunotherapy M.	Tsoumakidou (GR)



# 3<sup>rd</sup> International Meeting on Lung Cancer October 21-22 2022

16 30-18 00 <b>SF</b>	SSION 4.	Liquid Biopsy in Lung Cancer	
		leti (UK), F. Papageorgiou (GR)	
16.	30-17.00	The biologic and clinical relevance of CTCs in Lung Cano The relevance of ctDNA for the detection of	cer E. Lianidou (GR)
		Minimal Residual Disease in NSCLC Value of ctDNA for the monitoring of treatment efficacy	Ch. Abbosh (UK)
		advanced/metastatic NSCLC	P. Savvides (US)
18.00-18.20 <b>Co</b>	ffee Br	eak	
		Biomarkers in lung cancer Current or Future Resea ukas (GR), M. Tsoumakidou (GR)	rch Projects
18.	20-18.35	Messenger-RNA expression of BRCA1, RRM1, RRM2, h CDA genes predicting outcome to gemcitabine-based	ENT1, dCK and
18.	35-18.50	chemotherapy in advanced-stage NSCLC Clinical significance of Patras Immunotherapy Score	G. Ioannidis (CY)
		(PIOS) in NSCLC	I. Pyrousis (GR)
		Collaborative Project on Lung Tumor Microenvironment and Immune Response in	G. Skoulidis (US)
17.	.UJ-17.ZU	Lung Cancer	M. Koukourakis (GR)
19.20-19.45 <b>Inv</b>			
		inakis (GR), M. Rovithi (GR)	
Ma	ichine lear	ning in systems approaches for lung cancer	V. Megalooikonomou (GR)
Saturday	, 22	October 2022	
		The Kinome and Lung Cancer (I) Itsakis (GR), E. Sarris (GR)	
		ASSURIS (SIL), E. SUITIS (SIL)	
		Targeting KRAS-Driven NSCLC Current treatment and perspectives in	P. Economopoulou (GR)
09.	30-10.00	Targeting KRAS-Driven NSCLC	P. Economopoulou (GR)  A. Georgiou (UK)
09.	30-10.00	Targeting KRAS-Driven NSCLC Current treatment and perspectives in common EGFR-mutated NSCLC	
09.	30-10.00 00-10.30	Targeting KRAS-Driven NSCLC Current treatment and perspectives in common EGFR-mutated NSCLC Targeting EGFR Exon 20 Insertions and uncommon mutations in NSCLC	A. Georgiou (UK)
09. 10. 10.30-11.00 Co 11.00-12.30 SE	30-10.00 00-10.30 <b>ffee Br</b> <b>SSION 7:</b>	Targeting KRAS-Driven NSCLC Current treatment and perspectives in common EGFR-mutated NSCLC Targeting EGFR Exon 20 Insertions and uncommon mutations in NSCLC	A. Georgiou (UK)
09.  10.30-11.00 Co 11.00-12.30 SE	30-10.00 00-10.30 ffee Br SSION 7: derators:	Targeting KRAS-Driven NSCLC Current treatment and perspectives in common EGFR-mutated NSCLC Targeting EGFR Exon 20 Insertions and uncommon mutations in NSCLC eak The Kinome and Lung Cancer (II)	A. Georgiou (UK)
09. 10.30-11.00 <b>Co</b> 11.00-12.30 <b>SE</b> Mo	30-10.00 00-10.30 <b>ffee Br</b> <b>SSION 7:</b> derators: 00-11.30	Targeting KRAS-Driven NSCLC Current treatment and perspectives in common EGFR-mutated NSCLC Targeting EGFR Exon 20 Insertions and uncommon mutations in NSCLC eak The Kinome and Lung Cancer (II) G.Tsakonas (SE), I. Boukovinas (GR) Novel Therapeutics and Targeted Therapies in ALK positive NSCLC	A. Georgiou (UK) P. Christopoulos (DE) G. Ioannidis (CY)
09. 10.30-11.00 <b>Co</b> 11.00-12.30 <b>SE</b> Ma	30-10.00 00-10.30 <b>ffee Br</b> <b>SSION 7:</b> derators: 00-11.30	Targeting KRAS-Driven NSCLC Current treatment and perspectives in common EGFR-mutated NSCLC Targeting EGFR Exon 20 Insertions and uncommon mutations in NSCLC eak The Kinome and Lung Cancer (II) G.Tsakonas (SE), I. Boukovinas (GR) Novel Therapeutics and Targeted Therapies in ALK positive NSCLC Advances in treatment of HER2/NTRK/RET/ROS1/BRAF	A. Georgiou (UK) P. Christopoulos (DE) G. Ioannidis (CY)
09. 10. 10.30-11.00 Co 11.00-12.30 SE Mo 11.	30-10.00 00-10.30 <b>ffee Br</b> <b>SSION 7:</b> derators: 00-11.30 30-12.00	Targeting KRAS-Driven NSCLC Current treatment and perspectives in common EGFR-mutated NSCLC Targeting EGFR Exon 20 Insertions and uncommon mutations in NSCLC eak The Kinome and Lung Cancer (II) G.Tsakonas (SE), I. Boukovinas (GR) Novel Therapeutics and Targeted Therapies in ALK positive NSCLC	A. Georgiou (UK) P. Christopoulos (DE) G. Ioannidis (CY)



# 3<sup>rd</sup> International Meeting on Lung Cancer October 21-22 2022


12.30-13.30	SESSION 8: Mesothelioma and other malignancies Chairs: O.D. Røe (NOR), A. Boutis (GR)	
	12.30-13.00 Advances in treatment in malignant mesothelioma 13.00-13.30 Implementation of targeted therapies and immunotherapy	I. Metaxas (SUI)
	the treatment of thymic malignancies	S. Gennatas (UK)
13.30-15.00	Light Lunch	
15.00-15.45	SESSION 9: The Kinome and Lung Cancer (I) Advances in targeted therapies & new targets: Current or Future Research Moderators: F. Dimitrakopoulos(GR), G. Ioannidis (CY)	ch Projects
	15.00-15.15 Neuropilin 2, new applications for an old target 15.15-15.30 Deciphering immune infiltration in non-small cell lung carc 15.30-15.45 PD-L1 expression in CTCs from Lung cancer patients	A. Dimou (US) inomas I. Pateras (GR) G. Kallergi (GR)
15.45-17.45	Invited lectures Chairs: A. Psyrri, D. Papadatos-Pastos (UK)	
	15.45-16.10 Incorporating functional genomics in the treatment of NSCI 16.10-16.35 The Evolution of Metastases in NSCLC 16.35-17.00 The immune contexture and immunity in NSCLC 17.00-17.25 Combine radiotherapy with immunotherpay	.C G. Vasmatzis (US) M. Al Bakir (UK) A. Giatromanolaki (GR) M. Koukourakis (GR)
17.25-17.45	Coffee Break	
17.45-19.45	SESSION 10: Advances in Treatment of SCLC Chairs: A. Dimou (US), F. Koinis (GR)	
	17.45-18.15 SCLC Subgroups and Their Potential Clinical Significance 18.15-18.45 Current Strategies in ES-SCLC in the Frontline 18.45-19.15 Future perspectives in the treatment of SCLC	Dimitrakopoulos (GR) G. Imseeh (UK) K. Leventakos (US)
10 15 10 /5		N. Levelilakus (US)
17.13-17.43	Keynote Lecture Chairs: D. Papadatos-Pastos (UK), F.I. Dimitrakopoulos (GR)	
	Dissecting and targeting KRAS-mutant NSCLC	F. Skoulidis (US)
19.45	Closing Remarks	



# THE TOUGHEST CANCERS ARE AGGRESSIVE.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα συμπληρώνοντας την "ΚΙΤΡΙΝΗ ΚΑΡΤΑ"

νιαρέρετε κάθε όποιτη ανεπιθύμητη ενέργεια σύμφωνα με το εθνικό σύστυμα αναφοράς στο Τμήμα Ανεπιθύμητων Ενεργείων του Εθνικού Οργανιομού Φαμμίκων εθού Της 1230/0030 κα 21065-08650, ετα χρήσια της Κίτριαν Καρτισς διαθέσωμ αι στην ιστοιοελίδα του ΕΟΦ. www.eof.gr για έντυπη ή ηλειτρέσγου μποβολή ή



WE MUST BE RELENTLESS.

TAKING ON THE TOUGHEST CANCERS.

**AMGEN**°

Oncology

#### AMGEN HELLAS EПE

Αγ. Κωνσταντίνου 59-61 Green Plaza, κτίριο Γ 15 124 Μαρούσι Τηλ: 210 3447000 - Fax: 210 3447050 Email: info@amgen.gr, www.amgen.gr

GR-NPS-0621-00003



**3<sup>rd</sup> International Meeting on Lung Cancer October 21-22 2022** 

## Satellite Lecture

## Friday, 21 October 2022

09.00-09.30 Transforming the standard of adjuvant NSCLC treatment

A. Kotsakis (GR)

Sponsored by Roche





**ΦΑΡΜΑΣΕΡΒ-ΛΙΛΛΥ Α.Ε.Β.Ε.** Συνδεθ 15° χλμ. Εθνικής Οδού Αθηνών-Λαμίας,14564 Κηφισιά, **THA::** 210 6294600, **FAX::** 2106294610

Συνδεθείτε με τη ΦΑΡΜΑΣΕΡΒ-ΛΙΛΛΥ στα κοινωνικά δίκτυα



## 3<sup>rd</sup> International Meeting on Lung Cancer October 21-22 2022

## **FACULTY**

Abbosh Ch. Astrazeneca, Cambridge, UK

Al Bakir M. Clinical Lecturer in Medical Oncology, UCLH and UCL Cancer Institute, Clinical Research Fellow, Francis Crick Institute

**Boleti K.** MD, PhD, FRCP, Consultant in Medical Oncology & Lead for Acute Oncology, Department of Oncology, Royal Free London NHS Foundation Trust, UK

Boukovinas I. MD, PhD, PharmaD, Medical Oncologist, Head of Oncology Unit, Bioclinic Thessaloniki, Greece

**Boutis A.** MD, PhD, Consultant Medical Oncologist, 1st Department of Medical Oncology, Theageneio Cancer Hospital, Thessaloniki, Greece

Charalambous C. BM, MRCP, FRCR, Consultant Clinical Oncologist, Bank of Cyprus Oncology Centre, Nicosia, Cyprus

**Christopoulos P.** Professor of Medicine at Heidelberg University, MD, PhD, Hematologist & Medical Oncologist in the Thoraxklinik and National Center for Tumor Diseases (NCT) at Heidelberg University Hospital, Germany

**Dimitrakopoulos F. I.** MD, PhD, Medical Oncologist, Division of Oncology & Molecular Oncology Laboratory, Department of Medicine, University of Patras, Greece

**Dimou A.** MD, Senior Associate Consultant, Division of Medical Oncology, Assistant Professor of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA

**Economopoulou P.** MD, PhD, Consultant Medical Oncologist, 2<sup>nd</sup> Department of Internal Medicine, Attikon University Hospital, Greece

Evangelou G. Medical Oncologist, MB, MsC, 3<sup>rd</sup> Department of Medicine, Sotiria Hospital, Athens, Greece

Fortis S. Cancer Research Center, Immunology Department, Saint Savvas Cancer Hospital, Athens, Greece

**Foukas P.** Associate Professor of Pathology, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece

**Gennatas S.** BSc, MBChB, MRCP(UK), PhD, Consultant Medical Oncologist with a Specialist Interest in Thoracic Cancers and Acute Oncology, Guy's and St Thomas' NHS Foundation Trust, UK

**Georgiou A.** MBChB, PhD, BSc, MRCP, Consultant Medical Oncologist Guy's and St Thomas's and Kings College Hospitals, Honorary Senior Lecturer King's College, London, UK

**Giatromanolaki A.** Professor of Pathology, Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece


Imseeh G. Consultant Clinical Oncologist in Thoracic and Uro-Oncology, North Middlesex University Hospital NHS Trust, London, UK

**Ioannidis G.** MD, PhD, Director of the Oncology Department of Nicosia General Hospital, State Health Services Organization, Cyprus









TECENTRIQ® 1.200 mg: • Ελλάδα Ν.Τ.: 3.121,90 € - Λ.Τ.: 3.951,72 € • Κύπρος: Μ.Λ.Τ.: 4.073,42 € TECENTRIQ® 840 mg πυκνό διάλυμα για παρασκευή διαλύματος προς έγχυση.

TECENTRIQ® 840 mg: • Ελλάδα: N.T.: 2.053,66 € • Λ.Τ.: 2.618,66 € • Κύπρος: Μ.Λ.Τ.: 2.873,55 €



#### Τρόπος Διάθεσης ΤΕCENTRIQ®:

Με περιορισμένη ιατρική συνταγή: Μόνο για νοσοκομειακή χρήση από γιατρό με κατάλληλη ειδίκευση και εμπειρία. Περαιτέρω πληροφορίες διατίθενται από τον κάτοχο της άδειας κυκλοφορίας κατόπιν αιτήσεως.

#### Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και

Αναφέρετε: ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα Συμπληρώνοντας την «KITPINH KAPTA»

#### Ελλάδα: Roche (Hellas) A.E.

Αλαμάνας 4 & Δελφών, 151 25 Μαρούσι, Αττική τηλ: 210 6166100, email: hellas.medinfo@roche.com 800 111 93 00 (δωρεάν γραμμή επικοινωνίας)

Κύπρος: Γ.Α. Σταμάτης & Σία Λτδ. τηλ: +357 - 22 76 62 76



## 3<sup>rd</sup> International Meeting on Lung Cancer October 21-22 2022

Kallergi G. Assistant Professor of Biochemistry, Department of Biology, University of Patras, Greece

Kaparelou M. Medical Oncologist, Alexandra General Hospital, Athens Greece

Klinakis A. PhD. Investigator. Biomedical Research Foundation of the Academy of Athens. Greece

Koinis F. MD. PhD. Assistant Professor of Medical Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece

Korantzis I. Medical Oncologist, Agios Loukas Hospital, Thessaloniki, Greece

Kosmatopoulos K. Chief Executive Officer, Vaxon Biotech, Paris, France

Kotsakis A. MD, PhD, Associate Professor of Medical Oncology, Director of Department of Medical Oncology, University Hospital of Larisa, Thessaly, Greece

Koukourakis M. Professor of Radiotherapy and Oncology, Medical School, Democritus University of Thrace. Alexandroupolis, Greece

Leventakos K. MD, PhD, Assistant Professor, Chest oncology and clinical studies phase 1, Mayo Clinic, Rochester, USA

Lianidou E. PhD, Professor of Analytical Chemistry - Clinical Chemistry Analysis of Circulating Tumor Cells (ACTC) Lab Dept of Chemistry, University of Athens, Athens, Greece

Megalooikonomou V. Professor, Computer Engineering and Informatics Department, Director, Database Systems Laboratory, University of Patras, Greece

Metaxas I. MD, Senior Consultant Medical Oncology, Cantonal Hospital Muensterlingen, Switzerland

Røe D.O. D. MD, PhD, Professor, Cancer Clinic, Levanger Hospital, Nord-Trøndelag Health, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Norway

Papadatos-Pastos D. MRCP(UK) PhD, Consultant in Medical Oncology, Lung Cancer and Acute Oncology, University College London Hospitals and The Princess Alexandra Hospital, UK

Papageorgiou F. Biologist, PhD, Diagnostic Lead Oncology AstraZeneca, Greece

Pateras I. Pathologist, Assistant Professor, 2nd Department of Pathology, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Pyrousis I. Molecular Biologist, Research Fellow, Clinical and Molecular Oncology Laboratory, Medical School, University of Patras, Rion, Greece

Psyrri A. Professor of Internal Medicine and Medical Oncology, National Kapodistrian University of Athens, Chairman of Internal Medicine, Attikon Hospital, Athens, Greece

Rampias Th. PhD, Investigator, Assistant Professor Level, Biochemical Research Foundation Academy of Athens (BRFAA), Greece

Rovithi M. Medical Oncologist, Agios Nikolaos General Hospital, Crete, Greece



## **3rd International Meeting** on **Lung Cancer** October **21–22** 2022

Sarris E. MD, MSc, Medical Oncologist, Consultant 4th Oncology Department, Metropolitan Hospital, Athens, Greece

Savvides P. MD, PhD, MPH, Senior Associate Consultant, Thoracic H&N Medical Oncology, Mayo Clinic Arizona, USA

**Skoulidis F.** MD, PhD, Associate Professor, Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, USA

Tsakonas G. MD, PhD, Senior Consultant in Oncology, Karolinska University Hospital, Stockholm, Sweden

Tseveleki V. PhD, Chief Operating Officer, Theracell Advanced Biotechnology

Tsoumakidou M. MD, PhD, Group Leader - Institute of Bioinnovation, BSRC Alexander Fleming, Athens, Greece

**Vasmatzis G.** PhD, Consultant, Department of Molecular Medicine, Associate Professor of Molecular Medicine, Co-director of the Biomarker Discovery Laboratory within the Center for Individualized Medicine, Mayo Clinic, Rochester, NY, USA

**Verginis P.** Associate Professor, Immunology - Biochemistry, Laboratory of Immune Regulation and Tolerance, Medical School, University of Crete, Heraklion, Greece

Xagara A. Molecular Biologist, PhD, Laboratory of Oncology, Medical School, University of Thessaly, Larissa, Greece

**Ziogas D.** MD, PhD, Academic Scholar in Medical Oncology, 1<sup>st</sup> Department of Internal Medicine, Laikon General Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece



## 3<sup>rd</sup> International Meeting on Lung Cancer October 21-22 2022

## Info

#### Organized by



#### Under the auspices of







#### Date

October 21-22, 2022

#### Place

The Hybrid Event will take place at Golden Age Hotel (address: 57 Michalakopoulou Str., 11528, Athens, Greece)

#### Registration

Free

#### Official Language

The official language of the Hybrid Event is English

You can watch the Hybrid Event online through the Link www.livetime.gr and ask written guestions throughout the presentations

#### **Certificate of Attendance**

The certificate of attendance will be given to the participants at the end of the event. Based on the latest circular of the National Drug Organization the Event is required to use an attendance tracking system. By the end of the event a certificate will be given to those who have attended at least 60% of the total hours of the scientific Program. The number of credits of Continuing Medical Education (CME-CPD) to be administered to the participants will be calculated on the basis of monitoring time.

#### The event will be awarded

By Hellenic Medical Association (Ph. M.A.) with 16 CME - CPD credits.

#### Secretariat



Scientific | Cultural Events & Publications T+30 210 7240039 E info@scep.gr

www.scep.gr



1



# 3<sup>rd</sup> International Meeting on Lung Cancer October 21-22 2022



## 3<sup>rd</sup> International Meeting on Lung Cancer October 21-22 2022

## **SPONSORS**













PHARMACEUTICAL COMPANIES OF Johnson Johnson













NOTES

